Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial

Cancer Prevention Research

Volumn 2, Issue 4, 2009, Pages 310-321

  Bertagnolli, Monica M ^a   Eagle, Craig J ^c   Zauber, Ann G ^d   Redston, Mark ^a   Breazna, Aurora ^c   Kim, KyungMann ^e   Tang, Jie ^c   Rosenstein, Rebecca B ^c   Umar, Asad ^o   Bagheri, Donya ^f   Collins, Neal T ^c   Burn, John ^g   Chung, Daniel C ^b   Dewar, Thomas ^h   Foley, T Raymond ⁱ   Hoffman, Neville ^j   Macrae, Finlay ^k   Pruitt, Ronald E ^l   Saltzman, John R ^a   Salzberg, Bruce ^m   Sylwestrowicz, Thomas ⁿ   Hawk, Ernest T ^p   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c PFIZER INC   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f CCS Associates   (United States)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h Harris Methodist Fort Worth Hospital   (United States)

ⁱ Regional Gastroenterology Associates of Lancaster   (United States)

^j SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^k ROYAL MELBOURNE HOSPITAL   (Australia)

^l Nashville Medical Research Institute   (United States)

^m Atlanta Gastroenterology Associates   (United States)

ⁿ UNIVERSITY OF SASKATCHEWAN   (Canada)

^o NATIONAL CANCER INSTITUTE   (United States)

^p UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; PARACETAMOL; PLACEBO; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CANCER INCIDENCE; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PAIN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SHOCK; STROKE; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; VEIN THROMBOSIS; ADENOMA; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; TUMOR RECURRENCE;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COLONOSCOPY; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRAZOLES; SULFONAMIDES;

EID: 67549105888     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0206     Document Type: Article

References (23)

1. Winawer SJ, Zauber AG, O'Brien JM, et al, The National Polyp Study Workgroup. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Engl J Med 1993;328:901-906
2. Seeff LC, Nadel MR, Klabunde CN, et al. Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer 2004;100:2093-2103
3. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-179
4. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenopatous polyposis. N Engl J Med 2000;342:1946-1952 (Pubitemid 30419089)
5. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:1939. (Pubitemid 36297996)
6. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899
7. Arber N, Kuwada S, Leshno M, Sjodahl R, Hultcrantz R, Rex D. Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomized, double-blind, placebo controlled, dose-response study. Gut 2006;55:367-373 (Pubitemid 43268275)
8. Bertagnolli MM, Eagle CJ, Zauber AG, et al. A randomized trial of celecoxib to prevent sporadic colorectal adenomas. N Engl J Med 2006;355:873-884
9. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-1682
10. Flossman E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomized and observational studies. Lancet 2007;369:1603-1613
11. Henry D, Lim LL, Garcia Rodeiguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-1566 (Pubitemid 26188573)
12. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Pharmacol 1993;35:219-226
13. Silverstain FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;13:1247-1255 (Pubitemid 30691365)
14. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528 (Pubitemid 30844348)
15. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006;119:255-266 (Pubitemid 43255067)
16. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-674 (Pubitemid 39140622)
17. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102 (Pubitemid 40365350)
18. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080 (Pubitemid 40365348)
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
20. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS system. 2nd ed. Cary (NC): The SAS Institute; 2000.
21. Agresti A. Categorical Data Analysis. 2nd ed. New York: John Wiley & Sons, Inc.; 2002.
22. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-2270
23. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:612-614 (Pubitemid 36929412)